Quadruplet regimen for newly diagnosed multiple myeloma is effective in the standard-risk subgroup but not in the high-risk subgroup
-д хадгалсан:
Үндсэн зохиолчид: | Jianghua Ding (Зохиогч), Shengping Gong (Зохиогч) |
---|---|
Формат: | Ном |
Хэвлэсэн: |
Frontiers Media S.A.,
2024-05-01T00:00:00Z.
|
Нөхцлүүд: | |
Онлайн хандалт: | Connect to this object online. |
Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
Ижил төстэй зүйлс
-
Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways
-н: María Ortiz-Estévez, зэрэг
Хэвлэсэн: (2021) -
Optimizing Care for High-Risk Multiple Pregnancy with POCUS - A Case of Quadruplet Pregnancy Early Diagnosis
-н: Bernardo Vidal Pimentel, зэрэг
Хэвлэсэн: (2023) -
Bortezomib-Based Regimens for Newly Diagnosed Multiple Myeloma in China: A Report of 12-Year Real-World Data
-н: Jingsong He, зэрэг
Хэвлэсэн: (2020) -
Examining subgroup effects by socioeconomic status of public health interventions targeting multiple risk behaviour in adolescence
-н: Laura Tinner, зэрэг
Хэвлэсэн: (2018) -
Association of Acculturation with Cardiovascular Risk Factors in Asian-American Subgroups
-н: Yuemeng LI, зэрэг
Хэвлэсэн: (2023)